Previous studies have shown the appearance of a spontaneous luteinizing hormone (LH) surge after human chorionic gonadotrophin (HCG) administration in human menopausal gonadotrophin (HMG)/HCG-stimulated menstrual cycles. In this report we investigated the effect of leuprolide acetate, a long-acting luteinizing hormone releasing hormone (LHRH) agonist, on the occurrence of these post-HCG rises in serum LH. Two groups of patients were included. Group 1: 10 patients receiving HCG as a part of an HMG/HCG protocol for induction of follicular development in an IYF/GIFT program and Group II: 10 patients treated as Group I, but receiving the LHRH agonist leuprolide acetate to inhibit gonadotrophin secretion prior to and during ovarian stimulation. In Group I, none of the patients showed a surge prior to HCG administration. However, an LH surge following HCG treatment was apparent in four patients (40%). Pregnant patients (2/10) had low mean levels (<2.5 mIU/ml LH) in the follicular phase and showed no LH surge after HCG. In Group II, baseline levels of serum LH were reduced significantly (mean, 1.4 ± 0.1 mlU/ml; P < 0.001) compared to Group I. No patient showed an LH surge either before or after HCG administration and the occurrence of pregnancy was higher (6/9 transfers) than in Group I. In spite of the differences in pregnancy rates, the combined therapy versus HMG therapy showed no significant difference in number of oocytes collected or serum oestradiol levels. This suggests that high levels of serum LH, whether prior to or after HCG administration, may have a detrimental effect on the establishment of pregnancy despite adequate follicular growth. It is concluded that treatment with LHRH agonist prior to and during HMG stimulation reduces baseline concentrations of serum LH and abolishes post-HCG surges in serum LH. These effects were associated with a significantly higher pregnancy rate compared to treatment with HMG/HCG alone.
Introduction
The occurrence of spontaneous luteinizing hormone (LH) surges in human menopausal gonadotrophin (HMG)/human chorionic gonadotrophin (HCG)-stimulated menstrual cycles is controversial. While some investigators report the absence of an LH surge (Fowler et al., 1978; Ferraretti et al., 1983) , others indicate that this phenomenon may occur in a large percentage of patients (Vargyas et al., 1984; Van Uem et al., 1986) . In these studies, monitoring of the LH surge was limited to serum samples collected prior to HCG administration as measurement of LH by conventional radioimmunoassays (RIA) is impaired by the cross-reactivity with HCG. Consequently, the incidence of spontaneous LH surges after HCG was not determined.
Recently, we showed that a combination of an immunoradiometric assay (IRMA) and monoclonal antibodies with high affinity for human LH is an effective method of quantifying serum LH in the presence of HCG (Rojas et al., 1988) . Compared with conventional RIA, the assay showed no cross-reactivity in vitro at HCG concentrations normally found in serum after hormone treatment and was several orders of magnitude more effective in discriminating between human LH and HCG in vivo. Application of the assay to quantify serum LH before and after HCG administration in women receiving HMG/HCG indicated the absence of an LH surge prior to HCG administration. In contrast, an LH surge after HCG was apparent in a significant number of patients (Rojas et al., 1988) . Although the clinical significance of these post-HCG rises in serum LH remains to be established, these data suggest that an endogenous LH surge in response to normal or above normal concentrations of oestradiol is not abolished, but rather delayed in women with normal feedback mechanisms (Rojas et al., 1988) .
Prolonged administration of luteinizing hormone releasing hormone (LHRH) agonists has been shown to inhibit endogenous pituitary gonadotrophin secretion by hypophyseal desensitization (Wildt et al, 1981; Yen, 1983) . In the present study, this approach was used to investigate the effect of leuprolide acetate, a long-acting LHRH agonist, on the occurrence of post-HCG rises in serum LH during HMG/HCG ovarian stimulation. Data were compared to a group of patients treated with the same HMG/HCG protocol, but not receiving the LHRH agonist. The effects of leuprolide acetate were also evaluated with regard to serum oestradiol concentrations during follicular development, number of oocytes collected and pregnancy rate.
Materials and methods
Twenty women undergoing multiple follicular development as part of an IVF/GIFT program at the UCI-AMI Center for Reproductive Health were included in the study. A summary of the patient population is shown in Table I . Women were divided into two groups. Group I consisted of 10 patients receiving HMG (Pergonal, Serono Laboratories, Inc., Randolph, MA) 150 IU daily, i.m. from day 3 of the menstrual cycle. Group II consisted of 10 patients treated as Group I, but receiving the LHRH agonist leuprolide acetate (Takada-Abbot Products, 1 mg, s.c, daily) from day -8 of the menstrual cycle and during ovarian stimulation. All women received medication until vaginal ultrasound revealed at least two follicles > 16 mm diameter, and serum oestradiol levels were > 600 pg/ml. Then, HCG at a dose of 10 000 IU (Profasi, Serono Laboratories) was administered to induce the final stages of oocyte maturation. HCG was administered, in general, ~30 h after the last dose of HMG (22.00 h). Laparoscopy, follicular puncture and oocyte aspiration were performed 36 h post-HCG, as described in detail elsewhere (Asch etai, 1986) . Quantitative determination of serum LH was carried out using two monoclonal antibodies incorporated in an IRMA (LH MAIA Clone, Serono Diagnostics, Norwell, MA) according to procedures described previously (Rojas et al., 1988) . Results expressed as mlU/ml of the 1st International Reference Preparation (IRP) 68/40. Sensitivity of the assay was 0.3-0.5 mlU/ml. Intra-assay variability was 3 and 2% at mean levels of 5 and 85 mlU/ml, respectively. At the same mean levels, interassay variability was 10 and 8%, respectively.
Serum levels of oestradiol were determined by direct radioimmunoassay (Pantex Corp., Santa Monica, CA). The minimum concentration of oestradiol detectable was 10 pg/ml. The intraassay variability was 6% (range 5-7%), and the inter-assay variability was 10% (range 7-13%).
The date of HCG administration served as the arbitrary base (day 0) for normalizing hormone data. An LH surge or initiation of LH surge was defined by either an LH value exceeding the mean + 2 SD of all preceding values, or an LH rise > 12 mlU/ml (Rojas et al., 1988) . The latter criterion is based on the range (1-12 mlU/ml) of tonic, preovulatory levels of Measured daily for three consecutive days before HCG injection; mean ± SEM. b P < 0.001 compared to Group 1. serum LH described by others (Testart et al., 1981; Beastall et al., 1987; Van Uem et al., 1987) .
Comparison between means to test statistical differences was performed by either the two-tailed /-test or by analysis of variance, followed by Duncan's multiple range test. Differences between groups were considered to be significant at P < 0.05.
Results
Baseline serum LH concentrations prior to HCG administration in patients receiving HMG/HCG only (Group I) and in combination with the LHRH agonist (Group II) are shown in Table  II . Mean LH values varied considerably from one patient to another. This was particularly evident in Group I where a wide range of LH concentrations was observed. Despite these individual variations, serum LH levels in Group II were significantly lower than those in Group I. Accordingly, mean LH values in Group II decreased by a factor of 2.9. LH concen- trations were well within the range of preovulatory levels reported by others (Van Uem et al., 1987) and an LH surge or initiation of an LH surge prior to HCG administration was not apparent in either of the groups. The occurrence of an LH surge following HCG administration is shown in Table III . Four patients from Group I showed an LH surge either at 12 or 36 h after HCG injection. In contrast, none of the patients from Group II showed a post-HCG surge. Serum LH levels after HCG in Group II were similar to those determined prior to HCG administration (data not shown). This latter observation supports previous data demonstrating that the measurement of LH by monoclonal antibodies incorporated into an IRMA was not biased by the exogenously administered HCG (Rojas et al., 1988) .
Daily determinations of serum oestradiol during follicular development are shown in Figure 1 . Oestradiol values in patients from Group II were apparently higher than those from Group I. The difference, however, was not statistically significant. Interestingly, the two groups also presented a similar pattern of serum oestradiol. Thus, irrespective of the protocol used, serum oestradiol increased continually during HMG administration, reached the highest concentrations 12 h after HCG injection, and then decreased by 36 h after HCG (Figure 1 ). The number of oocytes collected and pregnancy outcome are shown in Table IV . A considerable individual variation was observed in the number of oocytes collected. Mean values, however, were not significantly different between the two groups. The occurrence of pregnancy, on the other hand, was significantly higher in patients from Group II. Accordingly, while six of the nine patients undergoing transfer became pregnant in Group II, only two of the 10 patients became pregnant in Group I (Table  IV) .
Discussion
Monitoring the LH surge and its characteristics may provide a better understanding of the functioning of the hypothalamicpituitary unit during ovarian stimulation and the mechanisms regulating the growth of follicles. In the present study we used a highly specific LH assay to investigate the effect of the longacting LHRH agonist, leuprolide acetate, on the occurrence of post-HCG rises in serum LH during ovarian stimulation using HMG/HCG.
Compared to a group of patients treated with HMG/HCG alone, treatment with the LHRH agonist prior to and concomitant with HMG administration decreased baseline concentrations of serum LH and completely abolished the endogenous LH surge occurring after the HCG injection. These data agree with previous studies indicating that prolonged administration of an LHRH agonist can inhibit endogenous pituitary gonadotrophin secretion (Wildt et al., 1981; Yen, 1983) and demonstrate that this hypogonadotrophic state is not altered by the administration of either HMG or HCG during ovarian stimulation.
Failure to detect serum LH rises following HCG administration in patients treated with HMG/HCG in combination with LHRH agonist indicates that exogenous HCG per se cannot account for the occurrence of a post-HCG surge in serum LH during HMG stimulation. Because a characteristic inhibition in LH secretion occurs during HMG treatment (Jones, 1984; Littman and Hodgen, 1984) , these data suggest that HCG is unable to overcome the mechanisms involved in this inhibition. The results presented here, therefore, do not favor a previous argument that HCG may facilitate LH secretion during HMG stimulation by reducing inhibin production by the follicles (Rojas et al., 1988) .
The absence of a detectable rise in serum LH after HCG administration also demonstrates that HCG, or its heterogeneous forms derived from metabolism in vivo, do not interfere with the determination of LH. This effectiveness of the LH assay to quantify serum LH in the presence of HCG agrees with previous data (Rojas et al., 1988) and provides further support for the use of monoclonal antibodies incorporated in an IRMA as the method of choice for the routine monitoring of LH secretion during ovarian stimulation with gonadotrophins.
The present study also indicates that the inhibitory effects of the LHRH agonist upon baseline LH levels and the endogenous LH surge occurring post-HCG administration were associated with a significantly higher pregnancy rate. Accordingly, 66.6% (6/9) of the transfers resulted in pregnancy in patients receiving a combination of HMG/HCG and the LHRH agonist. In comparison, the outcome of pregnancy was only 20% (2/10) in patients treated with HMG/HCG alone. These data are consistent with studies indicating that the combined therapy tends to prevent premature luteinization and leads to an improved chance of pregnancy (Yen, 1983; Wildtef al., 1986; Fleming etai, 1988) . Despite the differences in pregnancy rates, however, the combined therapy and HMG therapy showed no significant difference in the number of oocytes collected or in serum oestradiol concentrations. These data strongly suggest that high levels of serum LH, whether prior to or following HCG administration, have a detrimental effect on the establishment of pregnancy in stimulated cycles despite adequate follicle growth. Additional support for this concept is provided by the observation that the two patients who became pregnant in the group receiving HMG/HCG alone also showed both, low (<2.5 mlU/ml) serum LH levels during the late follicular phase and the absence of an LH surge after HCG administration.
In summary, we have shown that treatment with an LHRH agonist prior to and concomitant with HMG stimulation reduces LH secretion and eliminates the occurrence of post-HCG surges in serum LH. These effects were associated with a significantly higher pregnancy rate compared to a protocol using HMG/HCG alone. A larger number of cases will be needed to establish the real incidence of post-HCG rises in serum LH during HMG/HCG stimulation and its significance for oocyte development and clinical management of patients undergoing IVF/GIFT.
